Indication:
Indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Dosage Forms:
10mg 50mg INJ
Indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Dosage Forms:
10mg 50mg INJ